2012 revenue: $7.2 billion
2011 revenue: $7.6 billion
Year in review: Another year, another drop in sales for Boston Scientific ($BSX), this time with a 5% plunge. And Boston Scientific responded to those tepid numbers (and the device tax) in early 2013 by disclosing it would lay off as many as 1,000 more people in the coming months as it continues to restructure. But new CEO Michael Mahoney focused on the positive, noting improved 2012 fourth-quarter numbers for the struggling medical device giant. During that period, overall sales dropped 1% year-over-year, to $1.82 billion for the three-month period. While sales for interventional cardiology and cardiac rhythm management continued to drop, the company experienced solid and even robust gains in areas including endoscopy sales, neuromodulation and peripheral interventions. Boston Scientific has focused on acquisitions and emerging markets in order to boost its revenue and diversify, and that strategy will continue into 2013.
Boston Scientific targets another 1,000 jobs in expanded restructuring